Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
← catalyst calendarSponsored by Omeros Corporation (industry) · OMER — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
18estimated
Sites
16
Countries
Germany, Israel, Netherlands +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-01 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Thrombotic Microangiopathies
- Hematopoietic Stem Cell Transplantation
Intervention
- Drug: Biological: narsoplimab — also filed as Narsoplimab
Primary outcome
what the primary-completion date above is the date OF100-day survival rate following high-risk HSCT-TMA diagnosis.
measured 100 days
Permalink · OMER's whole pipeline · Catalyst calendar · Every registered study · What changed